Lebanon HIV Therapeutics Market Analysis Report [2022-30]

Lebanon HIV Therapeutics Market Analysis

$ 3999

The Lebanon HIV therapeutics market is expected to reach $xx Mn by 2030, up from $xx Mn in 2022, with a CAGR of xx % from 2022 to 2030. Local players such as Hikma Pharmaceuticals, Medis Pharma, and Pharaonia Pharmaceuticals dominate the HIV therapeutics market in Lebanon. Government policies, funding, and initiatives to manage HIV infections in the country propel market growth. The HIV therapeutics market in Lebanon is divided into four segments: type, product, geography, end user, and distribution channel.

ID: IN10LBPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Lebanon AUTHOR: Dr. Vishwa Modhia

Buy Now

Lebanon HIV Therapeutics Market Analysis Summary

The Lebanon HIV therapeutics market is expected to reach $xx Mn by 2030, up from $xx Mn in 2022, with a CAGR of xx % from 2022 to 2030.

Lebanon is a Middle Eastern country on the eastern shore of the Mediterranean Sea. It shares borders with Syria and Israel. In 2020, Lebanon's adult HIV/AIDS prevalence was less than 0.1 %, with 2700 HIV cases. Antiretroviral therapy is used by 63 % of HIV patients. According to the most recent WHO data, HIV/AIDS deaths in Lebanon reached 51, or 0.15 % deaths in 2020. Lebanon ranks 119th in the world with an age-adjusted death rate of 0.74 per 100,000 population.

According to the Ministry of Public Health, Lebanon imports approximately 80% of its pharmaceutical products, spending more than $1 Bn per year. Lebanon spent 8% of its GDP on healthcare in 2020.

Market Dynamics

Market Growth Drivers

As part of its efforts to reduce stigma and discrimination against people living with HIV/AIDS, Lebanon's National AIDS Control Program (NAP) established a center for the distribution of HIV/AIDS medications that is separate from the Ministry's dispensary. The NAP dispensary team is always in constant contact with drug companies to ensure the ongoing sustainability and availability of treatment for people living with HIV/AIDS. These factors may entice new entrants into Lebanon's HIV therapeutics market.

Market Restraint

The ongoing economic crisis in Lebanon has resulted in a critical medication shortage. Since October 2019, the Central Bank of Lebanon has been subsidizing (by making hard currency from its foreign reserves available) pharmaceutical imports into Lebanon. However, the Central Bank has reduced the amount available for these subsidies, resulting in massive shortages and higher prices for available medication. These factors may discourage new entrants into Lebanon's HIV therapeutics market.

Competitive Landscape

Key Players

Pharaonia Pharmaceuticals (LBN)
Medis Pharma (LBN)
Hikma Pharmaceuticals (LBN)
Gilead Sciences
AbbVie
Roche

Healthcare Regulations and Reimbursement Policies

In Lebanon, the Ministry of Public Health (MoPH) is the primary government body in charge of HIV therapeutics regulation. The Ministry of Public Health is in charge of evaluating and approving all medications, including HIV medications, based on their safety, efficacy, and quality, as well as setting standards for drug manufacturing and distribution in Lebanon. The MoPH also establishes guidelines and standards for HIV treatment and care in the country, as well as supervises the distribution of HIV drugs and other medical supplies to healthcare facilities.

The National Social Security Fund (NSSF) is the main government body in Lebanon in charge of HIV therapeutics reimbursement. The NSSF provides insurance coverage for a variety of healthcare services, including antiretroviral therapy and other HIV-related medical services. Qualification for NSSF insurance coverage is based on employment status and other criteria, and the specific guidelines for eligibility may vary depending on the individual's circumstances.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.